Vyvgart Insurance Denied? Appealing Efgartigimod Coverage for Myasthenia Gravis

Vyvgart (efgartigimod alfa) is an FcRn (neonatal Fc receptor) antagonist approved by the FDA in December 2021 for adults with generalized myasthenia gravis (gMG) who test positive for anti-AChR antibodies. It works by reducing levels of pathogenic IgG antibodies — including the anti-AChR antibodies that attack the neuromuscular junction in myasthenia gravis — by blocking their recycling via the FcRn pathway. Vyvgart is also available in a subcutaneous formulation (Vyvgart Hytrulo), approved in June 2023.

Myasthenia gravis can be debilitating and life-threatening, with crises causing respiratory failure. Despite its FDA approval and strong clinical trial data, Vyvgart is frequently denied by commercial insurers due to its cost, Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements, and step therapy barriers.

Why Insurers Deny Vyvgart

Step therapy requirements. Most commercial insurers require documentation that a patient has failed or has inadequate responses to conventional immunosuppressive therapies such as pyridostigmine, corticosteroids (prednisone), azathioprine, mycophenolate mofetil, and rituximab before approving Vyvgart. The step therapy requirements are often multi-drug and multi-year, which can delay access significantly.

Anti-AChR antibody status restriction. Vyvgart's FDA approval is specifically for anti-AChR antibody positive patients. Insurers may deny for anti-MuSK positive or seronegative patients on grounds that they are outside the label. (Note: Vyvgart Hytrulo has a broader approval for any antibody-positive gMG patients.)

"Not medically necessary" denials. Insurers may argue that the patient's disease is not severe enough to warrant Vyvgart when managed with standard immunosuppressives, even when the treating neurologist disagrees.

Formulary exclusion. Specialty formularies may not include Vyvgart, leading to administrative denials separate from medical necessity determinations.

IV versus subcutaneous formulation disputes. Coverage policies may differ between Vyvgart (IV) and Vyvgart Hytrulo (SQ), and the preferred formulation may differ by benefit category.

FDA Approval and Regulatory Status

Vyvgart received FDA approval on December 17, 2021, for adult patients with generalized myasthenia gravis who are anti-AChR antibody positive. It was the first FcRn antagonist approved for any indication. Vyvgart Hytrulo received approval in June 2023 for both anti-AChR and anti-MuSK positive gMG, broadening the population.

The approval was based on the ADAPT Phase 3 randomized controlled trial, which enrolled 167 adult patients and demonstrated statistically significant improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, with 68% of Vyvgart patients achieving a meaningful response compared to 30% of placebo patients.

Vyvgart holds FDA Orphan Drug Designation for myasthenia gravis and Fast Track Designation. Cite these in your appeal to directly rebut any experimental characterization.

Building Your Appeal

Neurologist letter of medical necessity. Your treating neurologist should document the gMG diagnosis (with anti-AChR antibody positivity confirmed by laboratory testing), MGFA classification (disease severity), Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, and prior treatment history — including all failed immunosuppressive therapies with specific doses, durations, and reasons for inadequate response or discontinuation.

Anti-AChR antibody laboratory results. Include the actual laboratory report showing anti-acetylcholine receptor antibody levels. This directly addresses the FDA label requirement.

ADAPT trial data. Published results in Lancet Neurology (Howard et al., 2021) demonstrate the 68% response rate versus 30% placebo. Attach or cite the publication.

Step therapy exhaustion documentation. If step therapy is the denial basis, provide complete records for each required prior therapy. For each medication: start date, end date, maximum dose reached, reason for discontinuation (insufficient response, adverse effects), and neurologist assessment of outcome.

Myasthenic crisis risk documentation. If the patient has had prior myasthenic crises, IVIG or plasma exchange for acute management, hospitalizations, or intubations, document these extensively. This establishes disease severity and urgency.

Neurology specialty society guidance. The American Academy of Neurology (AAN) and Myasthenia Gravis Foundation of America (MGFA) have published treatment guidelines. Cite any sections supporting advanced therapy for inadequately controlled gMG.

Expedited Review Rights

Myasthenia gravis with active weakness, dysphagia, or respiratory compromise constitutes a clinical urgency. If the patient has had recent myasthenic crises, is hospitalized, or has declining respiratory function, request expedited internal review with a 72-hour deadline. Your neurologist should document that delay risks myasthenic crisis with potential respiratory failure.

External Independent Review: Complete Guide" class="auto-link">External Review

After internal appeal denial, external review by a neurologist with neuromuscular disease expertise can assess whether the denial is clinically justified. For an FDA-approved therapy with Orphan Drug Designation and a landmark randomized controlled trial, denials based on step therapy or "not medically necessary" grounds are often successfully overturned.

Patient Assistance Programs

argenx, the manufacturer of Vyvgart, offers the myMG Support program providing insurance navigation, financial assistance, and a free drug bridge program for eligible patients. Contact argenx patient support immediately upon denial.

The Myasthenia Gravis Foundation of America (MGFA) offers insurance advocacy resources and can connect patients with experienced advisors. NORD provides rare disease financial assistance. Academic neuromuscular disease centers can provide expert letters to support appeals.

Fight Back With ClaimBack

Myasthenia gravis can take your breath away — literally. A denial for Vyvgart when standard immunosuppressives are not working is not acceptable. ClaimBack helps you build a thorough, persuasive appeal that puts the clinical evidence and your rights at the center.

Start your appeal at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: Which Should You File?